{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T17:06:26Z","timestamp":1768496786824,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.oret.2025.06.016","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:20:33Z","timestamp":1751455233000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics and Outcomes of Patients with Neovascular Age-Related Macular Degeneration by Anti-VEGF Exposure in United States Clinical Practice"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-7167","authenticated-orcid":false,"given":"Anita","family":"Barikian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya B.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2609-3991","authenticated-orcid":false,"given":"April J.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2402-6374","authenticated-orcid":false,"given":"Fabiana Q.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Tanenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Moini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2-a suppl","key":"10.1016\/j.oret.2025.06.016_bib1","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.oret.2025.06.016_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.06.016_bib3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","article-title":"Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records","volume":"127","author":"Kiss","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.06.016_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.06.016_bib5","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/IAE.0000000000000548","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the TWIN study","volume":"35","author":"Souied","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.06.016_bib6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","article-title":"Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 eyes","volume":"6","author":"Ciulla","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.06.016_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.06.016_bib8","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.06.016_bib9","article-title":"Impact of anti-vEGF treatment and patient characteristics on vision outcomes in neovascular age-related macular degeneration: up to 6-year analysis of the AAO IRIS\u00ae registry","volume":"4","author":"Wykoff","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2025.06.016_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/2474126420960896","article-title":"Visual acuity outcomes in patients receiving frequent treatment of neovascular age-related macular degeneration in clinical practice","volume":"5","author":"Moshfeghi","year":"2020","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.oret.2025.06.016_bib13","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1038\/s41598-019-38934-8","article-title":"Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment","volume":"9","author":"Wecker","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.06.016_bib14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.oret.2018.05.005","article-title":"Racial differences in age-related macular degeneration and associated anti-vascular endothelial growth factor intravitreal injections among medicare beneficiaries","volume":"2","author":"Mahr","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.06.016_bib15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3928\/23258160-20210330-05","article-title":"Racial differences in anti-vEGF intravitreal injections among commercially insured beneficiaries","volume":"52","author":"Al-Moujahed","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2025.06.016_bib16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40123-020-00288-0","article-title":"Demographic and clinical factors that influence the visual response to anti-vascular endothelial growth factor therapy in patients with neovascular age-related macular degeneration: a systematic review","volume":"9","author":"Gill","year":"2020","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025003100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025003100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:29:50Z","timestamp":1768444190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025003100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2468653025003100"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.06.016","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and Outcomes of Patients with Neovascular Age-Related Macular Degeneration by Anti-VEGF Exposure in United States Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}